Breast Cancer News
In this section, access cutting-edge triple-negative breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Each December, medical experts and researchers from around the world meet at the 5-day San Antonio Breast Cancer Symposium to share the latest findings from breast cancer clinical trials. Read on for updates from the 2013 symposium, held December 10–14.
(Reuters) - Women with an especially deadly type of breast cancer who received a treatment regimen containing an experimental AbbVie Inc drug prior to surgery are likely to have a significantly better response than those who get a standard chemotherapy regimen, according to data from a clinical trial.
A study suggests age-specific incidences of breast cancer subtypes vary by race, showing that the differences by race occur only when tumor subtypes are grouped together.
Research shows younger women given pre-surgical, or neoadjuvant, chemotherapy are more likely to have a complete response to that treatment than older women.
Learn about results from two studies that show adding bevacizumab (Avastin) to chemotherapy before surgery improves the rate of pathologic complete response in HER2 negative breast cancer that has not traveled to other parts of the body.
NEW YORK (Reuters Health) - Women with breast cancer who take common blood pressure drugs may have better odds of surviving the disease, according to two preliminary studies.
CHICAGO (Reuters) - Scientists know that being overweight increases the risk of breast cancers fed by estrogen, but being too fat may also increase the risk of triple-negative breast cancers, a less common and far more deadly type, U.S. researchers said on Tuesday.
MILAN (Reuters) - An established targeted therapy for bowel cancer may also help women with an aggressive form of breast cancer, a mid-stage clinical study revealed on Monday, opening up a potential new market for the medicine.
PARP inhibitors, added to chemotherapy, show promise in treating metastatic triple-negative breast cancer.